Clinical Research Directory
Browse clinical research sites, groups, and studies.
Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Summary
Treatment for Calciphylaxis Patients with Human Amniotic-derived Mesenchymal Stem Cells
Official title: Effects of Human Amniotic-derived Mesenchymal Stem Cells (hAMSCs) on Calciphylaxis Patients: An Open-Label Single-Arm Study
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
9
Start Date
2018-09-17
Completion Date
2028-09-17
Last Updated
2026-03-04
Healthy Volunteers
No
Interventions
Human amniotic-derived mesenchymal stem cells
(1) Intravenous infusion: 1.0×10⁶ cells/kg administered three times consecutively at weeks 1, 2, and 4, followed by once every 4 weeks for a total of 8 doses (6 months). (2) Local injection: 2.0×10⁴ cells/cm² of wound area, administered concurrently. Treatment may be terminated earlier or extended based on clinical condition.
Locations (1)
The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital
Nanjing, Jiangsu, China